Research Paper Volume 12, Issue 7 pp 5792—5811

Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML

Figure 8. Overall survival and disease free survival according to FLT3 mutations. (A) Overall survival in FLT3 mutated compared to FLT3 wild-type patients. (B) Disease free survival in FLT3 mutated compared to FLT3 wild-type patients. (C) Overall survival in patients with FLT3-ITD mutations in the absence of NPM1 mutations compared to others. (D) Disease free survival in patients with FLT3-ITD mutations in the absence of NPM1 mutations compared to others.